精彩内容抗体类药物已成为生物药中增长最快的类别之一。米内网数据显示，2025Q1~Q3中国三大终端六大市场抗体类药物销售额超860亿元，同比涨幅19.78%。公立医疗机构品牌TOP20中，12个独家品种（含剂型独家，下同）上榜，信达的信迪利单抗注射液首摘桂冠，复星、齐鲁等表现亮眼；零售药店品牌TOP20中，正大天晴的独家注射剂暴涨357%，荣昌、百济神州等实力不俗。石药、恒瑞、华海......39...
Source Link精彩内容抗体类药物已成为生物药中增长最快的类别之一。米内网数据显示，2025Q1~Q3中国三大终端六大市场抗体类药物销售额超860亿元，同比涨幅19.78%。公立医疗机构品牌TOP20中，12个独家品种（含剂型独家，下同）上榜，信达的信迪利单抗注射液首摘桂冠，复星、齐鲁等表现亮眼；零售药店品牌TOP20中，正大天晴的独家注射剂暴涨357%，荣昌、百济神州等实力不俗。石药、恒瑞、华海......39...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.